WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

Falzon D., Jaramillo E., Schünemann H.J., Arentz M., Bauer M., Bayona J., Blanc L., Caminero J.A., Daley C.L., Duncombe C., Fitzpatrick C., Gebhard A., Getahun H., Henkens M., Holtz T.H., Keravec J., Keshavjee S., Khan A.J., Kulier R., Leimane V., Lienhardt C., Lu C., Mariandyshev A., Migliori G.B., Mirzayev F., Mitnick C.D., Nunn P., Nwagboniwe G., Oxlade O., Palmero D., Pavlinac P., Quelapio M.I., Raviglione M.C., Rich M.L., Royce S., Rüsch-Gerdes S., Salakaia A., Sarin R., Sculier D., Varaine F., Vitoria M., Walson J.L., Wares F., Weyer K., White R.A., Zignol M.

Source: Eur Respir J 2011; 38: 516-528
Journal Issue: September
Disease area: Respiratory infections

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Falzon D., Jaramillo E., Schünemann H.J., Arentz M., Bauer M., Bayona J., Blanc L., Caminero J.A., Daley C.L., Duncombe C., Fitzpatrick C., Gebhard A., Getahun H., Henkens M., Holtz T.H., Keravec J., Keshavjee S., Khan A.J., Kulier R., Leimane V., Lienhardt C., Lu C., Mariandyshev A., Migliori G.B., Mirzayev F., Mitnick C.D., Nunn P., Nwagboniwe G., Oxlade O., Palmero D., Pavlinac P., Quelapio M.I., Raviglione M.C., Rich M.L., Royce S., Rüsch-Gerdes S., Salakaia A., Sarin R., Sculier D., Varaine F., Vitoria M., Walson J.L., Wares F., Weyer K., White R.A., Zignol M.. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
MDR-TB guidelines: what is new on clinical management
Source: ERS Webinar 2020: MDR-TB guidelines: what is new on clinical management
Year: 2020


Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016

Tuberculosis: cost of illness in Germany
Source: Eur Respir J 2012; 40: 143-151
Year: 2012



Psychiatric issues during the treatment of the patients with multidrug-resistant tuberculosis
Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis
Year: 2005


Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia)
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015

HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015

A novel nurse-led approach improves treatment completion rates for latent tuberculosis infection (LTBI) treatment
Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches
Year: 2014



Frequency of rifampicin resistance in re-treatment cases of pulmonary tuberculosis using Gene-Xpert in a tertiary care hospital tuberculosis clinic
Source: International Congress 2015 – WHO guidelines in TB and clinical practice
Year: 2015


Prospects for early implementation of ambulatory treatment in XDR TB patients by optimizing the administration of linezolid at the intensive phase of chemotherapy
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015


Cross-border management of tuberculosis cases through an updated ERS/WHO TB consilium
Source: International Congress 2015 – WHO guidelines in TB and clinical practice
Year: 2015


Adherence to the recommendation of prescribing 4 drugs in the intensive phase of the standard treatment of tuberculosis in Spain
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3
Year: 2014


Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016

ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use
Source: Eur Respir J 2014; 44: 811-815
Year: 2014


Centralization of M/XDR-TB care in clinical reference centres in Portugal. Experience of a regional reference centre
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015


Epidemiology and clinical management of XDR-TB: a systematic review by TBNET
Source: Eur Respir J 2009; 33: 871-881
Year: 2009



Current status of fluoroquinolone use for treatment of tuberculosis in Korea
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013

The global response to rifampicin-resistant tuberculosis: Current situation and recent trends
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016


Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe
Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology
Year: 2016



Current approaches to formulate evidence-based recommendations: a case study of WHO drug-resistant tuberculosis treatment guidance
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018



The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis
Source: Eur Respir J 2016; 48: 963-971
Year: 2016